Skip to content
Review Open access

Revisiting Glutathione Transferases of Plasmodium as Potential Targets for Coadjuvant Therapies and the Development of New Antimalarials

Aug 2026 · Pharmaceuticals · Vol 19, pp. 1287 · 0 citations · 108 references
Medicine

TL;DR

This review aims to synthesize current biochemical, structural, genetic, and transcriptomic evidence on Plasmodium glutathione S-transferases and evaluate their role in parasite physiology across the life cycle while revising their potential for drug targeting using suggested guidelines for target candidate profiling and prioritization.

Abstract

Malaria remains a major global health problem, especially in low- and mid-income countries where Plasmodium parasites are commonly endemic. Despite the significant number of available drugs to treat the disease, some aspects, such as increasing resistance to frontline antimalarials, inefficient treatment of asymptomatic carriers and treatment inadequacy for certain vulnerable groups, are jeopardizing control measures, justifying the need for therapeutic targets driving the discovery of new compounds. In this context, glutathione transferases, which are essential for redox metabolism and detoxification of heme in the asexual blood stages of Plasmodium parasites, have emerged as promising targets more than two decades ago, but have been deprioritized due to significant gaps in research. This review aims to synthesize current biochemical, structural, genetic, and transcriptomic evidence on Plasmodium glutathione S-transferases and evaluate their role in parasite physiology across the life cycle while revising their potential for drug targeting using suggested guidelines for target candidate profiling and prioritization.

Read PDF

Similar papers

Review Open access Sep 2026

Targeting Plasmodium falciparum pathways to overcome antimalarial resistance

The global burden of malaria remains substantial, exacerbated by the progressive emergence of resistance to frontline antimalarial therapies. Plasmodium falciparum , the most lethal malaria parasite, has developed reduced susceptibility to artemisinin-based combination therapies and several partner drugs, underscor...

PAUL CHIDOKA CHIKEZIE, F. O. Ohiagu, R. Ekeanyanwu et al. · 0 citations
Review Open access Sep 2026

"Redefining Leishmaniasis Therapy: Innovations in Drug Discovery and Vaccine Design".

Leishmaniasis remains a major neglected tropical disease that causes substantial morbidity and mortality worldwide, especially in resource-limited regions. Pentavalent antimonials, amphotericin B, miltefosine, pentamidine, and paromomycin are among the medications that continue to dominate the treatment landscape after...

Swati Pal, Shailesh Sharma, Ravinder Sharma · 0 citations
#artificial intelligence Review Open access Sep 2026

New thinking for the next generation of antimalarials

Despite decades of intensive research and substantial clinical gains, malaria remains a major global health challenge exacerbated by the continued emergence of drug-resistant strains of the causative agent, Plasmodium parasites. Encouragingly, recent advances in functional genomics, chemical biology and computational s...

Hannah Asiki, Jason Hlozek, K. Wicht et al. · 0 citations
Review Open access 2026

Green solution for malaria: Unveiling the therapeutic potential of natural products in antimalarial studies

Malaria remains a major global health challenge, with the continued emergence of antimalarial drug resistance underscoring the need for new, effective, and sustainable therapeutic strategies. Natural products have historically served as an important source of antimalarial agents, exemplified by quinine and artemisinin,...

Amina Jega Yusuf, Abdulrahman Abubakar Usman, Celestina Oluranti Alebiosu et al. · 0 citations
Open access Oct 2026

Screening of a chemogenetic library unveils dual-stage antiplasmodials with low cytotoxicity

ABSTRACT The global effort to eradicate malaria requires the development of drugs with novel mechanisms of action and differentiated pharmacological profiles. Both liver and blood phases of Plasmodium infection are essential for disease progression and transmission, making them primary targets for pharmacological inter...

Laura Torres, Matthew E. Fishbaugher, Mélanie Lam et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.